241 related articles for article (PubMed ID: 26541413)
1. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).
Penel-Page M; Ray-Coquard I; Larcade J; Girodet M; Bouclier L; Rogasik M; Corradini N; Entz-Werle N; Brugieres L; Domont J; Lervat C; Piperno-Neumann S; Pacquement H; Bay JO; Gentet JC; Thyss A; Chaigneau L; Narciso B; Cornille H; Blay JY; Marec-Bérard P
BMC Cancer; 2015 Nov; 15():854. PubMed ID: 26541413
[TBL] [Abstract][Full Text] [Related]
2. The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Eberst L; Cropet C; Le Cesne A; Pautier P; Penel N; Adenis A; Chevreau C; Bay JO; Collard O; Cupissol D; Duffaud F; Gentet JC; Piperno-Neumann S; Marec-Berard P; Bompas E; Thyss A; Chaigneau L; Cassier P; Bertucci F; Blay JY; Ray-Coquard I
BMC Cancer; 2014 Nov; 14():870. PubMed ID: 25420707
[TBL] [Abstract][Full Text] [Related]
3. Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Lebellec L; Chauffert B; Blay JY; Le Cesne A; Chevreau C; Bompas E; Bertucci F; Cupissol D; Fabbro M; Saada-Bouzid E; Duffaud F; Feuvret L; Bonneville-Levard A; Bay JO; Vauleon E; Vinceneux A; Noel G; Penel N; Mir O
Eur J Cancer; 2017 Jul; 79():119-128. PubMed ID: 28478340
[TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
5. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
6. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G; Palmerini E; Ferraresi V; D'Ambrosio L; Bertulli R; Asaftei SD; Tamburini A; Pignochino Y; Sangiolo D; Marchesi E; Capozzi F; Biagini R; Gambarotti M; Fagioli F; Casali PG; Picci P; Ferrari S; Aglietta M;
Lancet Oncol; 2015 Jan; 16(1):98-107. PubMed ID: 25498219
[TBL] [Abstract][Full Text] [Related]
8. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV.
Xing P; Zhang J; Yan Z; Zhao G; Li X; Wang G; Yang Y; Zhao J; Xing R; Teng S; Ma Y; Liao Z; Ren Z; Zhang C; Han X; Zhang W; Chen K; Wang P; Yang J
Oncotarget; 2017 May; 8(22):36716-36727. PubMed ID: 27888623
[TBL] [Abstract][Full Text] [Related]
9. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single-institution retrospective analysis.
Sugiyama M; Arakawa A; Shirakawa N; Tao K; Tanimura K; Nakajima M; Watanabe Y; Kumamoto T; Maniwa J; Yoneda A; Iwata S; Kobayashi E; Kawai A; Ogawa C
Pediatr Blood Cancer; 2023 Jul; 70(7):e30360. PubMed ID: 37073613
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma.
Duffaud F; Egerer G; Ferrari S; Rassam H; Boecker U; Bui-Nguyen B
Eur J Cancer; 2012 Mar; 48(4):564-70. PubMed ID: 22243773
[TBL] [Abstract][Full Text] [Related]
13. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Busch J; Seidel C; Kempkensteffen C; Johannsen M; Wolff I; Hinz S; Magheli A; Miller K; Grünwald V; Weikert S
Eur Urol; 2011 Dec; 60(6):1163-70. PubMed ID: 21802830
[TBL] [Abstract][Full Text] [Related]
14. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's).
Bétrian S; Bergeron C; Blay JY; Bompas E; Cassier PA; Chevallier L; Fayette J; Girodet M; Guillemet C; Le Cesne A; Marec-Berard P; Ray-Coquard I; Chevreau C
Clin Sarcoma Res; 2017; 7():10. PubMed ID: 28491276
[TBL] [Abstract][Full Text] [Related]
16. A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma.
Marec-Berard P; Dalban C; Gaspar N; Brugieres L; Gentet JC; Lervat C; Corradini N; Castex MP; Schmitt C; Pacquement H; Tabone MD; Brahmi M; Metzger S; Blay JY; Pérol D;
Eur J Cancer; 2020 Jan; 125():58-68. PubMed ID: 31838406
[TBL] [Abstract][Full Text] [Related]
17. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients.
Berger M; Grignani G; Ferrari S; Biasin E; Brach del Prever A; Aliberti S; Saglio F; Aglietta M; Fagioli F
Cancer; 2009 Jul; 115(13):2980-7. PubMed ID: 19452540
[TBL] [Abstract][Full Text] [Related]
19. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
